Selank

Overview

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed as a stabilized analog of tuftsin, a naturally occurring immune peptide, with additional amino acids added to slow its breakdown in the body.

It is most often discussed in the context of anxiety and cognition, where it has been studied for anxiolytic and nootropic properties. A distinguishing feature reported in the literature is that these effects appear without the sedation, tolerance, or dependence typically linked to conventional anti-anxiety drugs.

Selank is approved as a prescription anxiolytic in Russia but is not approved by the FDA or other major Western regulators. Much of the available evidence comes from Russian preclinical work and relatively small human studies, so its profile is best regarded as emerging.

How it works

In preclinical research, Selank appears to modulate several neurotransmitter systems rather than act on a single target. Reported mechanisms include influencing GABAergic signaling, altering serotonin and dopamine metabolism, and slowing the enzymatic breakdown of enkephalins, which may indirectly affect endogenous opioid and mood-regulating pathways.

Animal studies have also reported changes in brain-derived neurotrophic factor (BDNF) expression in regions such as the hippocampus and prefrontal cortex, which researchers have linked to its possible effects on memory and stress resilience. The precise mechanism in humans is not established.

Reported benefits

• Reduced anxiety without sedation (studied in generalized anxiety disorder and neurasthenia)
• Support for focus, memory, and mental clarity (largely animal and small-scale human data)
• A calming effect that, in studies, did not appear to produce dependence or withdrawal

These are reported and studied effects, not guaranteed outcomes.

Considerations & side effects

Because large, independent human trials are limited, the long-term safety profile of Selank is not well characterized outside the Russian clinical setting where it is approved. Reported side effects are generally described as mild, and studies have noted a low incidence of adverse effects, but this does not rule out risks that smaller studies may miss.

Product purity varies widely in the research-chemical market, and material sold for research use is not manufactured to pharmaceutical standards. Selank is not a substitute for evaluation and treatment by a qualified clinician.